Development of Adult T-Cell Leukemia/Lymphoma During Treatment with PD-L1 Inhibitor for Lung Cancer
Advancements in immunotherapy, the phenomenon of hyperprogression in cancer patients, have garnered increasing attention. We herein report a case of acute adult T-cell leukemia/lymphoma (ATL) that developed after administration of the programmed death-ligand1 inhibitor durvalumab in a patient with lung cancer. Although the patient was a carrier of human T-cell leukemia virus type 1 (HTLV-1), this was unknown prior to durvalumab treatment. HTLV-1 bZIP factor was detected in formalin-fixed lymph node tissue, confirming the diagnosis of ATL. Our findings suggest a potential association between immune checkpoint inhibition and ATL development in HTLV-1 carriers.
Authors
- Masaya Akiyama
- Tadashi Kohyama
- Mana Ishizuka
- Ryota Kawai (ORCID: https://orcid.org/0000-0003-3880-762X)
- Hikari Fujioka
- Goh Tanaka (ORCID: https://orcid.org/0009-0004-9700-8945)
- Satoshi Yoshioka (ORCID: https://orcid.org/0000-0003-3664-6324)
- Ayako Kobayashi (ORCID: https://orcid.org/0009-0008-9917-5033)
- Yutaro Tanaka (ORCID: https://orcid.org/0000-0003-3154-170X)
- T. Nakahara
- Kennosuke Karube (ORCID: https://orcid.org/0000-0002-1205-858X)
- Kentaro Kikuchi (ORCID: https://orcid.org/0000-0002-2263-0711)
- Ken Sato (ORCID: https://orcid.org/0000-0002-8733-1384)
- M. Kajitani
Institutions
- Nagoya University (JP)
- Teikyo University (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2025-03-07
- DOI
- https://doi.org/10.2169/internalmedicine.5114-24
- Primary Topic
- T-cell and Retrovirus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00